When the buyout was completed, the management was able to acquire 12 important brand products from DuPont Merck. These medications include, Opana, Percodan and Percocet. Headed by three executives of the business, the company was also able to purchase all of the generic products manufactured by Endo Laboratories LLC. With the creation of the new business, the management came up with the name Endo Pharmaceuticals, Inc., which would later on evolve to become the Endo International Plc.
The company today has the following business segments as part of its operations: U.S. Generic Pharmaceuticals, International Pharmaceuticals, U.S. Branded Pharmaceuticals and Devices. There are currently five companies that are under the Endo International umbrella: SOMAR, Paladin Labs, AMS, Endo Pharmaceuticals and Qualitest. Together, these companies market some of the most trusted brands in the world for antivirals, antiparkinsons and anesthetics. The business continues to expand its operations by acquiring similar businesses. In 2014 alone, they were able to complete the acquisition of four businesses that are now part of the Endo International companies: Auxilium Pharmaceuticals, Grupo Farmaceutico Somar, DAVA Pharmaceuticals, Inc. and Boca Pharmacal.
Endo continues to develop, manufacture and market products that are both branded and generic and several medical devices that are all marketed through its operating companies. It maintains two global headquarters, one in Malvern, Pennsylvania and one in Dublin, Ireland. There are more than 5,000 people that the company employs, who help the business in generating its multi-billion dollar annualized revenue.